Drug Safety Monitoring for Liposomal Amphotericin B

Abstract

Liposomal amphotericin B is now the key drug for disease control of visceral leishmaniasis, also known as kala-azar, in the sub-Indian continent. However, a number of generic products are currently available. Compared that for with other chemical compounds, liposomal formation is a crucial process for appropriate drug delivery in this particular medicine. We recently received isolated clinical findings after treatment using one generic product of liposomal amphotericin B from an endemic area. Herein, we report the different characteristics of generic products of liposomal amphotericin B to the genuine brand product. The size of the liposomal particles of the generic product is not uniform and far from the expected drug delivery and toxicity values. This review introduces a potential inspection approach for when policy makers adopt generic liposomal amphotericin B products into their own country.